Health topic

Cytomegalovirus (CMV)

Consistent testing for improved patient care

A widespread virus

 

Cytomegalovirus (CMV) is a common virus found in people of all ages—more than half of all adults have been infected by the age of 40.1 CMV is carried latently for life and can be reactivated.

 

Weakened immune systems are more susceptible

 

While the virus generally does not cause problems for those with healthy, functioning immune systems, it can have serious consequences for immunocompromised people.

Some 20%-60% of solid organ transplant recipients develop a symptomatic CMV infection, typically during the first few months after transplantation.2 Patients can be infected through the donor organ, or the virus can be reactivated if previously present.

 

CMV assays clinicians can rely on

 

Reactivation of CMV after a transplant can be detected quickly and treated using antiviral drugs. When it comes to successfully managing the infection and helping transplant patients enjoy long, healthy lives, consistency in test results plays a vital role.

Roche is committed to helping deter the spread and reactivation of the Cytomegalovirus and provides WHO-standardized assays to detect and monitor the progression of CMV infections.

 

Informing effective CMV management

 

CMV infection is a leading cause of morbidity and mortality in patients following transplantation. Calibrating and reporting CMV DNA viral load in International Units per milliliter (IU/mL) has improved harmonization of results from different laboratories. However, management of active CMV infection is still hampered by limited commutability of results between reference materials and clinical samples, and a subsequent lack of evidence-based viral load thresholds.

Latest related news

Roche launches next-generation viral load assay for CMV in markets accepting the CE mark

Pleasanton, California, December 22, 2014

cobas® CMV assay offers unparalleled performance on the cobas® 6800/8800 Systems.

More

Related systems

cobas® 6800 System image

cobas® 6800 System

Transform your testing experience for IVD applications—just 2 simple user interactions per run and up to 8 hours of walk-away time.

More
cobas® 8800 System image

cobas® 8800 System

Unparalleled performance with minimal operator interaction revolutionizes the future of high-throughput applications. 

More

References

  1. Centers for Disease Control and Prevention (CDC). Cytomegalovirus (CMV) and Congenital CMV Infection. http://www.cdc.gov/cmv/index.html. Accessed Nov 3, 2016.
  2. Emovon OE, Baillie GM, Rajagopalan PR, Chavin, KD. Infections after kidney transplantation. CME Coverage, based on Renal Week 2002: American Society of Nephrology 35th Annual Meeting. http://www.medscape.com/viewarticle/445262. Accessed December 13, 2016. Medscape Transplantation. 2002.
Filter